7 Best Psychedelic Stocks to Buy According to Analysts
As the psychedelic drug industry shifts from a speculative niche to a potential part of mainstream healthcare, investors have started to keep a careful eye on it.
Definium Therapeutics Inc. (DFTX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 0 | $0 | 0% | |
| 2. | Quantinno Capital Hoon Kim | 0 | $0 | 0% | |
| 3. | OrbiMed Advisors Samuel Isaly | 0 | $0 | 0% | |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 0 | $0 | 0% | |
| 5. | Millennium Management Israel Englander | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.17 | 2,500 | $17,925.00 | 19,851 | 2024-12-05 | Filing | |
| $5.98 | 3,500 | $20,930.00 | 17,351 | 2024-08-23 | Filing | |
| $6.12 | 500 | $3,060.00 | 565,543 | 2024-08-20 | Filing | |
| $6.31 | 500 | $3,155.00 | 565,043 | 2024-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $45.03 | 13,008 | $585,750.24 | 320,571 | 2026-06-25 | Filing | |
| $45.03 | 3,013 | $135,675.39 | 209,487 | 2026-06-25 | Filing | |
| $45.03 | 29,208 | $1,315,236.24 | 1,098,246 | 2026-06-25 | Filing | |
| $45.03 | 10,035 | $451,876.05 | 503,282 | 2026-06-25 | Filing | |
| $45.03 | 2,867 | $129,101.01 | 174,633 | 2026-06-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,000 | $321,300 | 0% | |
| 2. | 1 | $1 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?
TheFly reported on June 23 that Robert W. Baird analyst Christopher Chen increased the price target on DFTX to $57 from $37 while maintaining an Outperform rating.
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
10 Stocks Paying Off Big Time
Ten stocks kicked off the trading week with strong gains, bucking a lackluster performance on the broader market, thanks to a flurry of positive industry news that spilled over to their stocks.
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q1 2026 Earnings Call Transcript
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q1 2026 Earnings Call Transcript May 7, 2026Definium Therapeutics, Inc. misses on earnings expectations.
9 Best Psychedelic Stocks to Buy in 2026
The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 Earnings Call Transcript February 26, 2026Definium Therapeutics, Inc. reports earnings inline with expectations.
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III
TheFly reported on January 30 that Jefferies initiated coverage of DFTX with a Buy rating and a $30 price target.
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.
Hedge Fund Resource Center